Urological cancer, Malmö
81 – 90 of 530
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Correlation between ADC, ADC ratio, and Gleason Grade group in prostate cancer patients undergoing radical prostatectomy : Retrospective multicenter study with different MRI scanners
(
- Contribution to journal › Article
-
Mark
Incidence and associated risk factors of venous thromboembolism after open and laparoscopic partial nephrectomy in patients administered short-period thromboprophylaxis : a Danish nationwide population-based cohort study
(
- Contribution to journal › Article
-
Mark
The role of phoenixin in the proliferation and migration of ectopic epithelial cells in vitro
(
- Contribution to journal › Article
-
Mark
suPARnostic : an advanced predictive tool for detecting recurrence in renal cell carcinoma
(
- Contribution to journal › Article
- 2022
-
Mark
Risk of hernia formation after radical prostatectomy : a comparison between open and robot-assisted laparoscopic radical prostatectomy within the prospectively controlled LAPPRO trial
(
- Contribution to journal › Article
-
Mark
Increasing rates of urinary- and bloodstream infections following transrectal prostate biopsy in South Sweden
(
- Contribution to journal › Article
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
Complete metabolic response with [18F]fluorodeoxyglucose-positron emission tomography/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer
(
- Contribution to journal › Article